SECTION 1. IDENTIFICATION

Product name : AVASTIN(R) Vials (400 mg)
Product code : 00010062575

Manufacturer or supplier’s details
Company name of supplier : Genentech, Inc.
Address : DNA Way 1
         : 94080 South San Francisco
         : CA
         : USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab</td>
<td>216974-75-3</td>
<td>2.5</td>
</tr>
<tr>
<td>Trehalose (D+)-, 2H2O</td>
<td>6138-23-4</td>
<td>6.0</td>
</tr>
<tr>
<td>Sodium phosphate, monobasic, monohydrate</td>
<td>10049-21-5</td>
<td>0.58</td>
</tr>
<tr>
<td>Phosphoric acid, sodium salt (1:2)</td>
<td>7558-79-4</td>
<td>0.12</td>
</tr>
<tr>
<td>Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.</td>
<td>9005-64-5</td>
<td>0.04</td>
</tr>
<tr>
<td>Water</td>
<td>7732-18-5</td>
<td>90.76</td>
</tr>
</tbody>
</table>
SECTION 4. FIRST AID MEASURES

General advice: Do not leave the victim unattended.

If inhaled: Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact: If on skin, rinse well with water.

In case of eye contact: Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed: Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed: None known.

Notes to physician: The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during firefighting: No information available.

Hazardous combustion products: In case of fire hazardous decomposition products may be produced such as:
Carbon oxides
Nitrogen oxides (NOx)

Further information: Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Refer to protective measures listed in sections 7 and 8.
SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion: Normal measures for preventive fire protection.

Advice on safe handling: For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage: Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions: See label, package insert or internal guidelines

Materials to avoid: No materials to be especially mentioned.

Storage temperature: Protected from heat and light

Further information on storage stability: No decomposition if stored and applied as directed.

Packaging material: Suitable material: Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab</td>
<td>216974-75-3</td>
<td>IOEL</td>
<td>0.05 mg/m³</td>
<td>Roche Industrial Hygiene Committee (RIIHLC)</td>
</tr>
</tbody>
</table>

Engineering measures: No data available

Personal protective equipment

Respiratory protection: No personal respiratory protective equipment normally required.

Hand protection

Material: Protective gloves
### Remarks
- Wear appropriate protective gloves to prevent skin contact.
- Replace torn or punctured gloves promptly.

### Eye protection
- Safety glasses

### Skin and body protection
- Protective suit

### Hygiene measures
- Handle in accordance with good industrial hygiene and safety practice.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Appearance</strong></td>
<td>Aqueous solution, Clear liquid, Sterile liquid</td>
</tr>
<tr>
<td><strong>Color</strong></td>
<td>colorless</td>
</tr>
<tr>
<td><strong>Odor</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Odor Threshold</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>pH</strong></td>
<td>5.9 - 6.3</td>
</tr>
<tr>
<td><strong>Melting point/range</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Boiling point/boiling range</strong></td>
<td>ca. 212 °F / 100 °C</td>
</tr>
<tr>
<td><strong>Flash point</strong></td>
<td>does not flash</td>
</tr>
<tr>
<td><strong>Evaporation rate</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Self-ignition</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Upper explosion limit / Upper flammability limit</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Lower explosion limit / Lower flammability limit</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Vapor pressure</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Relative vapor density</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Relative density</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Density</strong></td>
<td>1.031 g/cm³</td>
</tr>
<tr>
<td><strong>Solubility(ies)</strong></td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>completely miscible</td>
</tr>
<tr>
<td>Solubility in other solvents</td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Partition coefficient: n-octanol/water</strong></td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET

AVASTIN(R) Vials (400 mg)

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue: 04-17-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>01-30-2020</td>
<td>Date of first issue: 12-04-2015</td>
</tr>
</tbody>
</table>

Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, dynamic : No data available
  Viscosity, kinematic : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
Chemical stability : Stable under normal conditions.
  Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created
  Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution
Possibility of hazardous reactions : Stable under recommended storage conditions.
  No hazards to be specially mentioned.
Conditions to avoid : Exposure to light.
Incompatible materials : No data available
Hazardous decomposition products : No data available

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity
Not classified based on available information.

Components:

Bevacizumab:
Acute oral toxicity : Remarks: Not bioavailable by oral administration
Acute toxicity (other routes of administration) : No-observed-effect level (cynomolgus monkey): 50 mg/kg
  Application Route: i.v.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.
Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

IARC
No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA
No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP
No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Bevacizumab:
Effects on fetal development:
Species: Rabbit
Application Route: i.v.
Result: Teratogenic effects., Embryotoxic effects.
Species: Humans
Application Route: i.v.
Result: Parenteral administration to pregnant women can cause fetal harm

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Bevacizumab:
Species: cynomolgus monkey
LOAEL: 2 mg/kg/w
Application Route: i.v.
Exposure time: 26 w
Remarks: Subchronic toxicity

Aspiration toxicity
Not classified based on available information.
SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Bevacizumab:
Toxicity to daphnia and other aquatic invertebrates
   EC50 (Daphnia magna (Water flea)): > 100 mg/l
   Exposure time: 48 h
   Method: OECD Test Guideline 202
   GLP: no

   NOEC (Daphnia magna (Water flea)): 100 mg/l
   Exposure time: 48 h
   Method: OECD Test Guideline 202
   GLP: no

Toxicity to algae/aquatic plants
   ErC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l
   Exposure time: 72 h
   Method: OECD Test Guideline 201
   GLP: no

   EyC50 (Desmodesmus subspicatus (green algae)): ca. 100 mg/l
   Exposure time: 72 h
   Method: OECD Test Guideline 201
   GLP: no

   NOEC (Desmodesmus subspicatus (green algae)): < 100 mg/l
   Exposure time: 72 h
   Method: OECD Test Guideline 201
   GLP: no

Toxicity to microorganisms
   (activated sludge): 100 mg/l
   Exposure time: 14 d
   Method: OECD Test Guideline 301F
   GLP: no
   Remarks: no adverse influence on substrate biodegradation

Persistence and degradability

Components:

Bevacizumab:
Biodegradability
   Result: Globular proteins are generally well biodegradable

   Concentration: 100 mg/l
   Theoretical oxygen demand
   Result: Readily biodegradable.
   Biodegradation: 78 %
   Exposure time: 28 d
   Method: OECD Test Guideline 301F
   GLP: no

   Concentration: 100 mg/l
Dissolved organic carbon (DOC)
Result: Readily biodegradable.
Biodegradation: 96%
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: no

Bioaccumulative potential

Components:
Bevacizumab:
Partition coefficient: n-octanol/water
Remarks: No data available

Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential
Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:
Bevacizumab:
Additional ecological information: Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Can be disposed as waste water, when in compliance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
SAFETY DATA SHEET

AVASTIN(R) Vials (400 mg)

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0</td>
<td>01-30-2020</td>
<td>04-17-2019</td>
<td>12-04-2015</td>
</tr>
</tbody>
</table>

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable

Domestic regulation

49 CFR
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Component RQ (lbs)</th>
<th>Calculated product RQ (lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphoric acid, sodium salt (1:2)</td>
<td>7558-79-4</td>
<td>5000</td>
<td>*</td>
</tr>
</tbody>
</table>

*: Calculated RQ exceeds reasonably attainable upper limit.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Component TPQ (lbs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARA 311/312 Hazards</td>
<td></td>
<td>No SARA Hazards</td>
</tr>
</tbody>
</table>

Clean Air Act
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act
The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:
  Phosphoric acid, sodium salt (1:2)  7558-79-4  >= 0.1 - < 1 %
The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:
  Phosphoric acid, sodium salt (1:2)  7558-79-4  >= 0.1 - < 1 %
This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307
SAFETY DATA SHEET

AVASTIN(R) Vials (400 mg)

Version 0.0  Revision Date: 01-30-2020  Date of last issue: 04-17-2019

Date of first issue: 12-04-2015

US State Regulations

Massachusetts Right To Know

Pennsylvania Right To Know

Water  7732-18-5
Trehalose (D+)-, 2H2O  6138-23-4
Phosphoric acid, sodium salt (1:2)  7558-79-4

Maine Chemicals of High Concern

Vermont Chemicals of High Concern

Washington Chemicals of High Concern

The ingredients of this product are reported in the following inventories:

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

      Bevacizumab

AICS : Not in compliance with the inventory

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Substance(s) not listed on TSCA inventory

TSCA list
No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION
SAFETY DATA SHEET

AVASTIN(R) Vials (400 mg)

Version 0.0

Revision Date: 01-30-2020

Date of last issue: 04-17-2019

Date of first issue: 12-04-2015

NFPA:

HMIS® IV:

Flammability

Health

Instability

Special hazard

HEALTH / 0

FLAMMABILITY 0

PHYSICAL HAZARD 0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The """" represents a chronic hazard, while the """" represents the absence of a chronic hazard.

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date: 01-30-2020

11 / 12
The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810